MedMira Attends FDA Public Workshop as Interest in its Multiplex Rapid Tests Continues to Increase

HALIFAX, April 11, 2013 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, is attending the US Food and Drug Administration Public Workshop on advances in multiplex testing taking place this week in Bethesda, MD.  Participation in this workshop is particularly timely, as MedMira advances a new multiplex rapid test for the simultaneous detection of HIV and Hepatitis B and C towards clinical trials and the FDA approval process under a United States Army Medical Research Acquisition Activity (USAMRAA) contract.  It is anticipated that various branches of the US military would use the test in emergency medical situations and for screening transfusion transmitted diseases.

The purpose of the FDA Public Workshop, planned in partnership with the AABB, Advanced Medical Technology Association (AdvaMed), America's Blood Centers, Department of Health and Human Services Offices of the Assistant Secretary of Health and the National Heart, Lung, and Blood Institute (NIH), is to discuss research and development of multiplex assays and the use of these tests in blood donor screening and blood cell antigen typing.

Since being awarded the USAMRAA contract to develop and commercialize the Multiplo HBc/HIV/HCV Rapid Antibody Test in 2012, the Company has seen a growing interest in its multiplex rapid tests and technology platform from various organizations and individual researchers in the US, and around the world.  The Company was also recently invited to submit its multiplex test for HIV and Syphilis to the World Health Organization (WHO) Prequalification of Diagnostics program.

"We receive several inquiries a week about our Multiplo product line from clinics, laboratories, life sciences researchers, and organ/tissue banks," said Neeraj Vats, Director of Technology and Business Affairs, MedMira Inc. "There are significant advantages in multiplex testing that these healthcare providers and researchers are looking for, including costs and time saving, the use of a single sample on one device, and the ability to screen for diseases that share similar infection paths such as blood and impact standard treatment regimens."

Vats continued, "Our multiplex rapid tests and technology platform, which surpass the capabilities of other rapid diagnostics on the market today, open up a fresh landscape for healthcare providers to radically increase their efficiency in diagnosing and treating patients."

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  This press release does not constitute any endorsement from the U.S. Army or the USAMRAA.

SOURCE MEDMIRA INC.

Copyright 2013 Canada NewsWire